
TURNING INVISIBLE RISKS INTO MEASURABLE TRUST.
.png)
150 million people worldwide rely on insulin – without knowing if it’s working as it should.
Every day, medicines lose their power silently, through heat, handling, and time.
We are devoloping a novel test with the power to shift healthcare beyond disease diagnostic, by making medication quality visible.

Reactive care vs. verified decisions with LUMIQ.

The problem is not temperature impact alone; it is decision-making under uncertainty.
Cold-chain data and temperature tracker shows risk. LUMIQ shows whether insulin quality is still intact.

Where innovation meets molecular biology.
Our journey began within the Insulin Activity Project at the Diabetes Center Berne, where we developed innovative methods to assess real-time insulin activity. Today, as a spin-off, we are transforming these insights into a pioneering solution for patients worldwide.

.png)
.png)
_edited.jpg)
Daniel Tobler
CTO & Operations
_edited.jpg)
Dr. Stefanie Dobitz
CSO & INSPIRE LAB Lead
_edited.jpg)
Dr. Maren Schinz
CEO & Business Dev
_edited.jpg)
Ema Grabenweger
CMO & Go-to-Market
.png)
OUR TEAM.

.png)
Three Converging Challenges Are Putting Medication Quality In Patients’ Hands At Risk..



¹ WHO Climate & Health Supply Chains Report, 2024, ² U.S. FDA CDER Novel Drug Approvals, 2023, ³ Grand View Research, Home Healthcare Market Analysis, 2024
.png)






_edited.jpg)












.png)